探讨PRKDC介导PI3K/AKT信号通路在鼻咽癌中的作用机制
Exploring the Mechanism by Which PRKDC Mediates the PI3K/AKT Signaling Pathway in Nasopharyngeal Carcinoma
DOI: 10.12677/acm.2025.15103018, PDF,   
作者: 许海龙*, 黄萍萍, 陈小素：右江民族医学院研究生学院，广西 百色；韦富贵#：广西科技大学第二附属医院(第二临床医学院)耳鼻咽喉头颈外科，广西 柳州
关键词: PRKDC；PI3K/AKT信号通路；鼻咽癌；分子机制；靶向治疗；PRKDC； PI3K/AKT Signaling Pathway； Nasopharyngeal Carcinoma； Molecular Mechanism； Targeted Therapy
摘要: 鼻咽癌是一种高度侵袭性和转移性的恶性肿瘤，其治疗效果受到肿瘤复杂的分子机制的限制。近年来，PRKDC (DNA依赖性蛋白激酶催化亚基)作为重要的DNA损伤修复因子，已被发现通过激活PI3K/AKT信号通路在鼻咽癌的发生发展中发挥着重要作用。研究表明，PRKDC不仅在肿瘤细胞的生存和增殖中扮演关键角色，还与多种信号通路的交互作用密切相关。本文综述PRKDC的生物学功能以及PI3K/AKT信号通路的作用机制，重点分析PRKDC介导PI3K/AKT通路激活的分子机制及其在鼻咽癌治疗中的潜在应用价值，为鼻咽癌的精准治疗提供理论依据和未来研究方向。
Abstract: Nasopharyngeal carcinoma is a highly aggressive and metastatic malignant tumor, and its treatment efficacy is limited by the complex molecular mechanisms of the tumor. In recent years, PRKDC (DNA-dependent protein kinase catalytic subunit) has been identified as an important DNA damage repair factor, playing a crucial role in the development and progression of nasopharyngeal carcinoma by activating the PI3K/AKT signaling pathway. Studies have shown that PRKDC not only plays a key role in the survival and proliferation of tumor cells but is also closely related to the interaction of multiple signaling pathways. This article reviews the biological functions of PRKDC and the mechanism of action of the PI3K/AKT signaling pathway, focusing on the molecular mechanisms by which PRKDC mediates the activation of the PI3K/AKT pathway and its potential application value in the treatment of nasopharyngeal carcinoma, providing theoretical basis and future research directions for precise treatment of nasopharyngeal carcinoma.
文章引用：许海龙, 韦富贵, 黄萍萍, 陈小素. 探讨PRKDC介导PI3K/AKT信号通路在鼻咽癌中的作用机制[J]. 临床医学进展, 2025, 15(10): 2339-2348. https://doi.org/10.12677/acm.2025.15103018

参考文献

[1] Kang, Y., He, W., Ren, C., Qiao, J., Guo, Q., Hu, J., et al. (2020) Correction: Advances in Targeted Therapy Mainly Based on Signal Pathways for Nasopharyngeal Carcinoma. Signal Transduction and Targeted Therapy, 5, Article No. 265. [Google Scholar] [CrossRef] [PubMed]
[2] Song, L., Liu, J., Shang, Y., Hu, Y., Zhang, J., Ye, Y., et al. (2024) Enhanced MRI Radiomics Based Model for Predicting Recurrence or Metastasis of Nasopharyngeal Cancer (NC) Undergoing Concurrent Chemoradiotherapy: A Retrospective Study. Cancer Control, 31, 1-7. [Google Scholar] [CrossRef] [PubMed]
[3] Chen, Y., Li, Y., Guan, Y., Huang, Y., Lin, J., Chen, L., et al. (2020) Prevalence of PRKDC Mutations and Association with Response to Immune Checkpoint Inhibitors in Solid Tumors. Molecular Oncology, 14, 2096-2110. [Google Scholar] [CrossRef] [PubMed]
[4] Kumar, K.R.R. (2023) Lost in the Bloom: DNA-PKCS in Green Plants. Frontiers in Plant Science, 14, Article 1231678. [Google Scholar] [CrossRef] [PubMed]
[5] Chen, D., Ren, H., Zhao, N. and Hao, J. (2023) Expression and Prognostic Value of DNA Sensors in Hepatocellular Carcinoma. Journal of Leukocyte Biology, 114, 68-78. [Google Scholar] [CrossRef] [PubMed]
[6] Tan, K.T., Yeh, C., Chang, Y., Cheng, J., Fang, W., Yeh, Y., et al. (2020) PRKDC: New Biomarker and Drug Target for Checkpoint Blockade Immunotherapy. Journal for Immuno Therapy of Cancer, 8, e000485. [Google Scholar] [CrossRef] [PubMed]
[7] Zhang, J., Jia, L., Tsang, C.M. and Tsao, S.W. (2017) EBV Infection and Glucose Metabolism in Nasopharyngeal Carcinoma. In: Advances in Experimental Medicine and Biology, Springer, 75-90. [Google Scholar] [CrossRef] [PubMed]
[8] Cao, Y. (2017) EBV Based Cancer Prevention and Therapy in Nasopharyngeal Carcinoma. npj Precision Oncology, 1, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
[9] Yu, G., Hsu, W.L., Coghill, A.E., Yu, K.J., Wang, C., Lou, P., et al. (2019) Whole-Exome Sequencing of Nasopharyngeal Carcinoma Families Reveals Novel Variants Potentially Involved in Nasopharyngeal Carcinoma. Scientific Reports, 9, Article No. 9916. [Google Scholar] [CrossRef] [PubMed]
[10] Yang, X., Yang, F., Lan, L., Wen, N., Li, H. and Sun, X. (2022) Potential Value of PRKDC as a Therapeutic Target and Prognostic Biomarker in Pan-Cancer. Medicine, 101, e29628. [Google Scholar] [CrossRef] [PubMed]
[11] Pang, W., Wang, Y., Lu, X., Li, M., Long, F., Chen, S., et al. (2025) Integrated Spatial and Single Cell Transcriptomics Identifies PRKDC as a Dual Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma. Scientific Reports, 15, Article No. 14834. [Google Scholar] [CrossRef] [PubMed]
[12] Ling, Z., Fang, Z., Wu, J. and Liu, J. (2021) The Depletion of Circ‐PRKDC Enhances Autophagy and Apoptosis in T‐cell Acute Lymphoblastic Leukemia via MicroRNA‐653‐5p/Reelin Mediation of the PI3K/AKT/mTOR Signaling Pathway. The Kaohsiung Journal of Medical Sciences, 37, 392-401. [Google Scholar] [CrossRef] [PubMed]
[13] Oh, T., Kang, G., Jo, H., Park, H., Lee, Y. and Ahn, G. (2024) DNA-Dependent Protein Kinase Regulates Cytosolic Double-Stranded DNA Secretion from Irradiated Macrophages to Increase Radiosensitivity of Tumors. Radiotherapy and Oncology, 193, Article 110111. [Google Scholar] [CrossRef] [PubMed]
[14] Li, B., Ding, Z., Calbay, O., Li, Y., Li, T., Jin, L., et al. (2023) FAP Is Critical for Ovarian Cancer Cell Survival by Sustaining NF-κB Activation through Recruitment of PRKDC in Lipid Rafts. Cancer Gene Therapy, 30, 608-621. [Google Scholar] [CrossRef] [PubMed]
[15] Zhang, Y., Shen, G., Zhang, D., Meng, T., Lv, Z., Chen, L., et al. (2025) N6-Methyladenosine Modification Mediated by METTL3 Promotes DNA-PKCS Expression to Induce Anlotinib Resistance in Osteosarcoma. Clinical and Translational Medicine, 15, e70228. [Google Scholar] [CrossRef] [PubMed]
[16] Xiong, J., Deng, C., Fu, Y., Tang, J., Xie, J. and Chen, Y. (2025) Prognostic and Potential Therapeutic Roles of PRKDC Expression in Lung Cancer. Molecular Biotechnology, 67, 2455-2466. [Google Scholar] [CrossRef] [PubMed]
[17] Chen, H., Pei, L., Xie, P. and Guo, G. (2020) Circ-PRKDC Contributes to 5-Fluorouracil Resistance of Colorectal Cancer Cells by Regulating miR-375/FOXM1 Axis and Wnt/β-Catenin Pathway. OncoTargets and Therapy, 13, 5939-5953. [Google Scholar] [CrossRef] [PubMed]
[18] Sun, E.J., Wankell, M., Palamuthusingam, P., McFarlane, C. and Hebbard, L. (2021) Targeting the PI3K/AKT/mTOR Pathway in Hepatocellular Carcinoma. Biomedicines, 9, Article 1639. [Google Scholar] [CrossRef] [PubMed]
[19] Ghafouri-Fard, S., Khanbabapour Sasi, A., Hussen, B.M., Shoorei, H., Siddiq, A., Taheri, M., et al. (2022) Interplay between PI3K/AKT Pathway and Heart Disorders. Molecular Biology Reports, 49, 9767-9781. [Google Scholar] [CrossRef] [PubMed]
[20] Savova, M.S., Mihaylova, L.V., Tews, D., Wabitsch, M. and Georgiev, M.I. (2023) Targeting PI3K/AKT Signaling Pathway in Obesity. Biomedicine & Pharmacotherapy, 159, Article 114244. [Google Scholar] [CrossRef] [PubMed]
[21] Huang, L., Yang, Q., Chen, H., Wang, Z., Liu, Q. and Ai, S. (2022) Tollip Promotes Hepatocellular Carcinoma Progression via PI3K/AKT Pathway. Open Medicine, 17, 626-637. [Google Scholar] [CrossRef] [PubMed]
[22] Bang, J., Jun, M., Lee, S., Moon, H. and Ro, S.W. (2023) Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma. Pharmaceutics, 15, Article 2130. [Google Scholar] [CrossRef] [PubMed]
[23] Liu, X., Zuo, H., Wu, C., Li, N., Zhou, Q., Cao, F., et al. (2025) Muscone Attenuates Uveitis through the PI3K/AKT Signaling Pathway. Investigative Ophthalmology & Visual Science, 66, 21. [Google Scholar] [CrossRef] [PubMed]
[24] Zhang, H., Pang, J., Zhang, Y., Ma, Y., Fan, F. and Liu, H. (2022) AZD9291 Suppresses Proliferation and Migration of Nasopharyngeal Carcinoma Cells by Inhibiting the PI3K-AKT-mTOR Pathway. Journal of Southern Medical University, 42, 1403-1409.
[25] Qin, Z.Q., Li, Q.G., Yi, H., et al. (2020) Heterozygous p53-R280T Mutation Enhances the Oncogenicity of NPC Cells Through Activating PI3K-AKT Signaling Pathway. Frontiers in Oncology, 10, Article 104. [Google Scholar] [CrossRef] [PubMed]
[26] Lin, T., Tao, Y.Y., Tang, Y.G., et al. (2025) Effect of Biyan Jiedu Capsules on Proliferation and Apoptosis of Nasopharyngeal Carcinoma Cells Based on PI3K/AKT Pathway. China Journal of Chinese Materia Medica, 50, 1920-1927.
[27] Xiong, Y., Zhong, W., Liu, J., Cheng, B., Fan, J., Zhou, F., et al. (2022) Luteolin Isolated from polygonum Cuspidatum Is a Potential Compound against Nasopharyngeal Carcinoma. BioMed Research International, 2022, e974066. [Google Scholar] [CrossRef] [PubMed]
[28] Wu, Y.T., Chen, L.C., Wang, H.H., et al. (2025) Scutellarein Enhances Cisplatin‑Induced Apoptotic Effects by Suppressing the PI3K/AKT‑MDR1 Pathway in Human NPC/HK1 Nasopharyngeal Carcinoma Cells. Biomedical Reports, 22, Article No. 60. [Google Scholar] [CrossRef] [PubMed]
[29] Pan, S., Zhang, X., Guo, Y. and Li, Y. (2022) DPCPX Induces Bim-Dependent Apoptosis in Nasopharyngeal Carcinoma Cells. Cell Biology International, 46, 2050-2059. [Google Scholar] [CrossRef] [PubMed]
[30] Shi, Y., Meng, X., Xu, Y. and Tian, X. (2021) Role of FOXO Protein’s Abnormal Activation through PI3K/AKT Pathway in Platinum Resistance of Ovarian Cancer. Journal of Obstetrics and Gynaecology Research, 47, 1946-1957. [Google Scholar] [CrossRef] [PubMed]
[31] Li, F., Yang, Y., Ge, J., Wang, C., Chen, Z., Li, Q., et al. (2024) Multi-Omics Revealed the Mechanisms of Codonopsis Pilosula Aqueous Extract in Improving UC through Blocking Abnormal Activation of PI3K/AKT Signaling Pathway. Journal of Ethnopharmacology, 319, Article 117220. [Google Scholar] [CrossRef] [PubMed]
[32] Luo, T., Chen, S., Ruan, Y., Chen, H., Chen, Y., Li, Y., et al. (2023) Downregulation of DDIT4 Ameliorates Abnormal Behaviors in Autism by Inhibiting Ferroptosis via the PI3K/AKT Pathway. Biochemical and Biophysical Research Communications, 641, 168-176. [Google Scholar] [CrossRef] [PubMed]
[33] Song, S., Fan, M., Wen, X., Shi, X., Lou, Y., He, Z., et al. (2023) Integrated Network Pharmacology and Gut Microbiome Analysis to Reveal the Mechanism of Qu-Zhuo-Tong-Bi Decoction against Hyperuricemia and Gout. Journal of Ethnopharmacology, 316, Article 116736. [Google Scholar] [CrossRef] [PubMed]
[34] Jiang, X., Yin, H., Su, W., Quan, H., Yuan, X., Feng, X., et al. (2023) Trifolirhizin Inhibits Proliferation, Migration and Invasion in Nasopharyngeal Carcinoma Cells via PI3K/AKT Signaling Pathway Suppression. Biochemical and Biophysical Research Communications, 667, 111-119. [Google Scholar] [CrossRef] [PubMed]
[35] Xie, J., Shi, Z., Sun, L., Wu, Y., Feng, J., Wang, H., et al. (2025) Fangchinoline Suppresses Nasopharyngeal Carcinoma Progression by Inhibiting SQLE to Regulate the PI3K/AKT Pathway Dysregulation. Phytomedicine, 140, Article 156484. [Google Scholar] [CrossRef] [PubMed]
[36] Castellano, G.M., Zeeshan, S., Garbuzenko, O.B., Sabaawy, H.E., Malhotra, J., Minko, T., et al. (2022) Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 21, 1381-1392. [Google Scholar] [CrossRef] [PubMed]
[37] Cao, C., Wang, Y., Wu, X., Li, Z., Guo, J. and Sun, W. (2022) The Roles and Mechanisms of Circular RNAs Related to mTOR in Cancers. Journal of Clinical Laboratory Analysis, 36, e24783. [Google Scholar] [CrossRef] [PubMed]
[38] Chen, W., Chen, W., Chen, S., Jiang, L., Shu, G., Yin, Y., et al. (2024) Establishment of a Visualized Mouse Orthotopic Xenograft Model of Nasopharyngeal Carcinoma. Cancer Biology & Therapy, 25, Article 2382531. [Google Scholar] [CrossRef] [PubMed]
[39] Li, D., Du, C., Lin, Y. and Wu, M. (2002) Inhibition of Growth of Human Nasopharyngeal Cancer Xenografts in SCID Mice by Arsenic Trioxide. Tumori Journal, 88, 522-526. [Google Scholar] [CrossRef] [PubMed]
[40] Hwang, Y., Lu, T., Huang, D., Kuo, Y., Kao, C., Yeh, N., et al. (2009) NOLC1, an Enhancer of Nasopharyngeal Carcinoma Progression, Is Essential for TP53 to Regulate MDM2 Expression. The American Journal of Pathology, 175, 342-354. [Google Scholar] [CrossRef] [PubMed]
[41] Zhang, W., Li, W., Yin, C., Feng, C., Liu, B., Xu, H., et al. (2024) PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT. Cancer Research, 84, 2873-2887. [Google Scholar] [CrossRef] [PubMed]
[42] Zhou, Y., Liu, F., Xu, Q., Yang, B., Li, X., Jiang, S., et al. (2020) Inhibiting Importin 4-Mediated Nuclear Import of CEBPD Enhances Chemosensitivity by Repression of PRKDC-Driven DNA Damage Repair in Cervical Cancer. Oncogene, 39, 5633-5648. [Google Scholar] [CrossRef] [PubMed]
[43] Zhang, J., Jiang, Y., Yu, Y. and Li, J. (2022) Preclinical Evaluation of the Dual mTORC1/2 Inhibitor Sapanisertib in Combination with Cisplatin in Nasopharyngeal Carcinoma. European Journal of Pharmacology, 915, Article 174688. [Google Scholar] [CrossRef] [PubMed]
[44] Wang, H., Guo, H.M., Wu, Q.L., Yan, H., Liu, G. and Gao, M. (2021) MicroRNA-203a-3p Affects the Biological Characteristics of Nasopharyngeal Carcinoma by Targeting Vascular Endothelial Growth Factor-C. Journal of Physiology and Pharmacology, 72, 605-613. [Google Scholar] [CrossRef] [PubMed]
[45] Zhang, J., Zhou, J. and Xiao, S. (2020) Shikonin Inhibits Growth, Invasion and Glycolysis of Nasopharyngeal Carcinoma Cells through Inactivating the Phosphatidylinositol 3 Kinase/AKT Signal Pathway. Anti-Cancer Drugs, 31, 932-941. [Google Scholar] [CrossRef] [PubMed]
[46] Peng, Y., Xia, J., Zhou, D., et al. (2024) S100A2 Upregulates GLUT1 Expression to Promote Glycolysis in the Progression of Nasopharyngeal Carcinoma. Histology and Histopathology, 39, 1669-1683.
[47] Sun, Y., Chen, K., Lin, G., Wan, F., Chen, L. and Zhu, X. (2021) Silencing C-Jun Inhibits Autophagy and Abrogates Radioresistance in Nasopharyngeal Carcinoma by Activating the PI3K/AKT/mTOR Pathway. Annals of Translational Medicine, 9, 1085-1085. [Google Scholar] [CrossRef] [PubMed]
[48] Fang, S., Peng, L., Zhang, M., Hou, R., Deng, X., Li, X., et al. (2024) MiR-2110 Induced by Chemically Synthesized Cinobufagin Functions as a Tumor-Metastatic Suppressor via Targeting fgfr1 to Reduce PTEN Ubiquitination Degradation in Nasopharyngeal Carcinoma. Environmental Toxicology, 39, 3548-3562. [Google Scholar] [CrossRef] [PubMed]

为你推荐